Gold prices rocketed to their highest point in two years, as investors continue to buy into the safe-haven on low/negative interest rates and lingering global economic concerns. Also fueling gold were comments from New York Federal Reserve President William Dudley who noted the bank would be patient on raising rates on the heels of low…
Over the last several days, global markets buckled under the strain of increased volatility, and uncertainty. It was a train wreck of emotional trading. Worldwide markets lost $3 trillion in two days. The Nikkei lost 1,280 points – the biggest drop in 16 years. The Dow Jones Industrial Average lost more than 800 points. European…
Over the last two trading sessions, we’ve seen the global community lose more than $2 trillion of value over the UK vote to leave the European Union. The news set off a firestorm of fear. The Dow Jones Industrial Average plummeted 800 points. The British pound fell to a 30-year low. Gold surged as expected. …
Just the other day, we spoke about Exact Sciences (EXAS), and the reasons for which the stock moved aggressively higher. While we made no recommendation to buy the stock at such an elevated price, we were careful to point out that it was another example of Wall Street hyping a stock to unrealistic prices because…
In September 1992, George Soros “broke the bank of England,” and raked in more than a billion dollars in a single day. All he did was short the pound. Nowadays, he’s warning that a UK exit from the EU could unleash a similar drop, perhaps by 15% to 20%. “The Brexit crash will make all…
In late 2014, shares of Pain Therapeutics plunged after Pfizer ended an agreement to help it develop and market the Remoxy pain drug along with Durect Corporation. The stock was left for dead, ignored. But things are rapidly improving. So much so, the stock rocketed from our recommended entry price of $1.83 in the July…
It may not be one of the most exciting stocks on the market. But it’s a moneymaker. The stock – Eletromed – develops, designs, manufacturers, and markets airway products, such as its SmartVest airway system to patients suffering from cystic fibrosis, bronchiectasis, pneumonia, and neuromuscular disorders, and to patients with post-surgical complications or is considered…
The buyout rumors are heating up. After the FDA granted approval for ACAD’s Parkinson’s disease Psychosis (PDP) treatment, the list of potential acquirers is getting longer. Not only is Pfizer, Biotgen, and Teva reportedly interested in the company, but now reports are surfacing that AstraZeneca may be a potential bidder, too. Sources say ACADIA may…
Over the last year, The Cheap Investor made a recommendation to buy Galena Biopharma (GALE) at just $1.33 in June 2015, and again at $1.67 in August 2015. As of today, the stock last traded at $2.29 for potential gains of 37% and 80%. The stock is tracking even higher after the FDA designated its…
In the November 2015 issue of The Cheap Investor, we made a recommendation to pick up shares of CPXX at just $1.75 a share. Just months later, the stock skyrocketed to a high of $17.69 for potential gains of 911% on news of successful Phase III clinical results for VYXEOS for patients with high risk…
As we near the June 2016 ASCO event in Chicago, Illinois, immunotherapy has again t taken center stage… especially as the FDA approves a treatment to help battle an advanced form of bladder cancer, know as urotherial carcinoma. Developed by Genentech, the treatment works by strengthening the body’s own immune, training it to attack bladder…
The buyout rumors are swirling. Pfizer (FPE), Biogen (BIIB) and Teva Pharmaceuticals (TEVA) are all reportedly interested in Parkinson’s disease Psychosis (PDP) drug stock, ACADIA Pharmaceuticals (ACAD). Analysts believe ACAD could see at least a $6 billion buyout offer after the FDA approved its PDP drug that could help up to 40% of all Parkinson’s…